Article
Clinical Neurology
Ahmad Shamabadi, Farnaz Kafi, Melika Arab Bafrani, Hassan Asadigandomani, Fatemeh A. Basti, Shahin Akhondzadeh
Summary: This study found that adjunctive L-theanine, when combined with sertraline, showed better efficacy in treating major depressive disorder (MDD) compared to placebo. The L-theanine group demonstrated significant improvement in depression symptoms and a greater reduction in depression scores compared to the placebo group at weeks 2, 4, and 6. Furthermore, the L-theanine group had higher remission and response rates at week 6. These findings suggest that L-theanine is a safe and effective adjunctive therapy for MDD.
JOURNAL OF AFFECTIVE DISORDERS
(2023)
Article
Neurosciences
Elan A. Cohen, Howard H. Hassman, Larry Ereshefsky, David P. Walling, Vera M. Grindell, Richard S. E. Keefe, Katarzyna Wyka, William P. Horan
Summary: The high and growing placebo response rates in clinical trials for CNS indications present a major challenge for drug development. This study found that educating participants about placebo response factors through the Placebo-Control Reminder Script (PCRS) can help mitigate placebo response rates and reduce the number of adverse events.
NEUROPSYCHOPHARMACOLOGY
(2021)
Article
Endocrinology & Metabolism
Xu He, Ruihuan Zhang, Zhe Li, Zhen Yao, Xiaoxia Xie, Ruoxue Bai, Lan Li, Xu Zhang, Sha Zhang, Yan Shen, Shaowei Li, Zhenliang Hui, Rongrong Liu, Jun Chen
Summary: Circadian rhythm disorder is a significant risk factor for mental diseases, and the recovery of circadian rhythm function has gradually become a signal of effective antidepressant therapy. This study explored the efficacy of Sini powder (SNP) on depression by regulating circadian rhythm. The results showed that SNP had a positive impact on improving circadian rhythms in patients with major depressive disorder.
JOURNAL OF PINEAL RESEARCH
(2022)
Article
Psychiatry
Sophia Attwells, Elaine Setiawan, Pablo M. Rusjan, Cynthia Xu, Stephen J. Kish, Neil Vasdev, Sylvain Houle, Apitharani Santhirakumar, Jeffrey H. Meyer
Summary: Oral minocycline did not significantly reduce TSPO V-T in TRD patients, suggesting that this dosage may be insufficient for reducing gliosis in this condition. Alternative therapeutic approaches or intravenous formulations of minocycline should be considered for targeting gliosis in TRD. Additionally, it should not be assumed that oral minocycline will reduce TSPO V-T or gliosis in humans without empirical evidence.
TRANSLATIONAL PSYCHIATRY
(2021)
Article
Medicine, General & Internal
Robin von Rotz, Eva M. Schindowski, Johannes Jungwirth, Anna Schuldt, Nathalie M. Rieser, Katharina Zahoranszky, Erich Seifritz, Albina Nowak, Peter Nowak, Lutz Jaencke, Katrin H. Preller, Franz X. Vollenweider
Summary: In this double-blind, randomized clinical trial, a single, moderate dose of psilocybin was found to significantly reduce depressive symptoms compared to a placebo condition for at least two weeks, with no serious adverse events recorded. Larger, multi-centric trials with longer follow-up periods are needed to further optimize this novel treatment paradigm.
Article
Clinical Neurology
P. N. Suresh Kumar, Vikas Menon, Chittaranjan Andrade
Summary: This study investigated the impact of vitamin D supplementation on depression treatment through a randomized controlled trial. The results showed that vitamin D supplementation did not improve the antidepressant effects of flexibly dosed escitalopram. Importantly, depressed patients with vitamin D deficiency may require higher antidepressant doses to experience similar benefits to those whose deficiency is corrected by vitamin D supplementation.
JOURNAL OF AFFECTIVE DISORDERS
(2022)
Article
Psychiatry
Gary S. Sachs, Paul P. Yeung, Ludmyla Rekeda, Arifulla Khan, Julie L. Adams, Maurizio Fava
Summary: This study aimed to investigate the efficacy of cariprazine as adjunctive therapy for patients with major depressive disorder and nonresponse to at least one antidepressant monotherapy. The results showed that cariprazine significantly reduced depressive symptoms with minimal adverse effects.
AMERICAN JOURNAL OF PSYCHIATRY
(2023)
Article
Psychology, Clinical
Anita H. Clayton, Robert Lasser, Indrani Nandy, Abdul J. Sankoh, Jeffrey Jonas, Stephen J. Kanes
Summary: This study evaluated the efficacy and safety of zuranolone in major depressive disorder. Significant improvements in depressive symptoms were observed with zuranolone at days 3, 8, and 12. Zuranolone was generally well tolerated in patients with MDD.
JOURNAL OF CLINICAL PSYCHIATRY
(2023)
Article
Clinical Neurology
Saba Hoobehfekr, Hossein Sanjari Moghaddam, Mohammadreza Shalbafan, Maryam Ghazizadeh Hashemi, Mohammad Mehdi Pirmoradi, Amirhossein Sakenian, Amirhossein Poopak, Shayan Kashefinejad, Masoomeh Yarahmadi, Shahin Akhondzadeh
Summary: Combination therapy of tipepidine with citalopram can effectively improve symptoms of patients with major depressive disorder in a shorter period of treatment, with higher rates of remission and response. There was no significant difference between the two groups in baseline parameters or frequency of side-effects. Further studies with larger sample sizes and longer follow-up treatment are needed to confirm these findings.
PSYCHIATRY AND CLINICAL NEUROSCIENCES
(2021)
Article
Biochemistry & Molecular Biology
Erhan Kavakbasi, Emma Sampson, Natalie T. Mills, Hikaru Hori, Kathrin Schwarte, Christa Hohoff, K. Oliver Schubert, Scott R. Clark, Celia Fourrier, Bernhard T. Baune
Summary: Low-grade inflammation is considered a pathophysiological mechanism in some patients with major depressive disorder. This study investigates the predictive value of pre-treatment hsCRP stratification on the outcome of celecoxib augmentation of vortioxetine in treating depression.
JOURNAL OF NEUROCHEMISTRY
(2023)
Article
Neurosciences
Mahmoud S. Abdallah, Ahmed N. Ramadan, Hend Omara-Reda, Noha O. Mansour, Mohamed A. Elsokary, Hozaifa K. Elsawah, Shimaa Abdelsattar Zaki, Hend E. Abo Mansour, Esraa M. Mosalam
Summary: Cilostazol has shown safe and effective antidepressant effects in patients with MDD, significantly reducing depression symptom scores, improving early response rates, and modulating various neurotrophic and inflammatory biomarkers.
CNS NEUROSCIENCE & THERAPEUTICS
(2021)
Article
Integrative & Complementary Medicine
Saeed Azizi, Neda Mohamadi, Fariba Sharififar, Gholamreza Dehghannoudeh, Farzaneh Jahanbakhsh, Fatemeh Dabaghzadeh
Summary: This study found that orally administered rosemary capsules have therapeutic effects in patients with major depressive disorder, improving symptoms of anxiety and depression. Rosmarinic acid, the main active component in rosemary, may contribute to these improvements.
COMPLEMENTARY THERAPIES IN CLINICAL PRACTICE
(2022)
Article
Clinical Neurology
Michael E. Thase, Paula L. Jacobsen, Elizabeth Hanson, Rengyi Xu, Max Tolkoff, Naga Venkatesha Murthy
Summary: For patients with major depressive disorder who achieved symptomatic remission with vortioxetine 10 mg/day, all doses of vortioxetine were effective for the prevention of relapse, with acceptable tolerability.
JOURNAL OF AFFECTIVE DISORDERS
(2022)
Article
Psychiatry
Weifeng Mi, Xiaolan Di, Yiming Wang, Huafang Li, Xiufeng Xu, Lehua Li, Huaning Wang, Guoqiang Wang, Kerang Zhang, Feng Tian, Jiong Luo, Chanjuan Yang, Yunfei Zhou, Shiping Xie, Hua Zhong, Bin Wu, Dong Yang, Zhenhua Chen, Yi Li, Jindong Chen, Shuyun Lv, Qizhong Yi, Zhiwei Jiang, Jingwei Tian, Hongyan Zhang
Summary: Major depressive disorder (MDD) is a common form of depression that poses a significant challenge to public health and medical practice. A clinical trial in China found that ansofaxine, a potential triple reuptake inhibitor, was effective and safe in treating adult MDD patients at doses of 80 mg/day and 160 mg/day.
TRANSLATIONAL PSYCHIATRY
(2023)
Article
Neurosciences
Aida Khadivi, Parnian Shobeiri, Sara Momtazmaneh, Farhaneh-Sadat Samsami, Mohammadreza Shalbafan, Elham Shirazi, Shahin Akhondzadeh
Summary: This study investigated the safety and efficacy of combining phosphodiesterase-3 inhibitor cilostazol with sertraline in the treatment of major depressive disorder (MDD). The results showed that patients in the cilostazol group had lower depression severity scores, higher remission rate, and faster response time compared to the placebo group. No serious adverse effects were observed.
PSYCHOPHARMACOLOGY
(2022)